Statement: Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events.
Primary_evidence: Adverse Events 1:   Total: 5/11 (45.45%)   Hemorrhage, GI-abdomen NOS 21/11 (9.09%)   Pain-liver 21/11 (9.09%)   Infection-ulcer 20/11 (0.00%)   Hemoglobin 20/11 (0.00%)   Hypoglycemia 20/11 (0.00%)   Pain-rib cage due to vomiting 20/11 (0.00%)   Obstruction-gu ureter 1/11 (9.09%)   Hemorrhage gu-bladder 21/11 (9.09%)   Pain-breast 21/11 (9.09%)   Pleural effusion 22/11 (18.18%) Adverse Events 2:   Total: 0/6 (0.00%)   Hemorrhage, GI-abdomen NOS 20/6 (0.00%)   Pain-liver 20/6 (0.00%)   Infection-ulcer 20/6 (0.00%)   Hemoglobin 20/6 (0.00%)   Hypoglycemia 20/6 (0.00%)   Pain-rib cage due to vomiting 20/6 (0.00%)   Obstruction-gu ureter 0/6 (0.00%)   Hemorrhage gu-bladder 20/6 (0.00%)   Pain-breast 20/6 (0.00%)   Pleural effusion 20/6 (0.00%)